Fewer than half of U.S. addiction treatment facilities offer cessation medication. New York’s new tobacco-limited rules show how unsettled the question is.
Key Takeaways
- The mortality gap: In a Mayo Clinic cohort of former inpatient addiction patients, tobacco-related causes accounted for half of the deaths, outpacing alcohol.
- The treatment gap: Fewer than half of U.S. substance use treatment facilities offered cessation medication in 2023, and about a third had fully tobacco-free grounds.
- The evidence: A University of California, San Francisco meta-analysis linked quit-smoking help during addiction treatment to a 25 percent higher likelihood of long-term sobriety.
- The policy split: Nineteen states require tobacco-free substance use facilities, while New York now lets adult programs permit scheduled, supervised smoking.
The guidance is specific enough to tape to the wall of a nurses’ station. In a New York adult residential addiction program that chooses to become “tobacco-limited,” patients may smoke cigarettes only in a designated outdoor area at least 100 feet from every entrance, during set windows the state calls nicotine dosing administrations. There can be no more than ten a day. None may run longer than five minutes or fall during a group or individual session. Staff hand out the lighters and take them back afterward, patients may not trade cigarettes for goods or services, and staff may not use a cigarette as a reward.
The rules come from the New York State Office of Addiction Services and Supports, and their author is what makes them notable. On July 24, 2008, New York became the first state to require every state-funded or state-certified addiction program, 1,419 of them by one research team’s count, to go completely tobacco-free, indoors and out. The regulation behind that mandate, 14 NYCRR Part 856, now carries the title “Tobacco Use in Adult Services,” and OASAS guidance dated November 4, 2025, lets adult programs attest that they meet criteria for limited cigarette smoking, provided they keep screening every patient, provide group treatment for tobacco use, and supply FDA-approved cessation medication. Programs serving children, adolescents, and young adults must remain tobacco-free.
The state that wrote the country’s strictest rule has built a supervised exception to it. On paper the change is modest. It lands, though, on a question addiction treatment has carried for decades without settling: whether the substance that kills more of its former patients than any other belongs inside the treatment plan.
Tobacco-Related Deaths After Addiction Treatment
The mortality evidence most often cited on that question is thirty years old. Richard Hurt and colleagues at the Mayo Clinic followed all 845 residents of Olmsted County, Minnesota, admitted to the clinic’s inpatient addiction program from 1972 through 1983, a group treated mostly for alcoholism. By the end of follow-up, 222 had died. Among the 214 deaths with a certificate on file, 50.9 percent had a tobacco-related underlying cause and 36.0 percent an alcohol-related one, according to the study as corrected after its publication in JAMA. Heart disease, emphysema, and lung cancer did more of the killing than the drug that had brought these patients to Mayo.
Smoking among people with substance use disorders has not receded the way it has across the general population. Using National Survey on Drug Use and Health data from 2002 through 2014, Andrea Weinberger, Renee Goodwin, and colleagues at Columbia University’s Mailman School of Public Health and the City University of New York reported in Addiction that 56 percent of people with a substance use disorder had smoked in the past month, compared with 18 percent of those without one. Excluding cannabis use disorder, the figure rose to 64 percent. Over those years smoking fell among people without a substance use disorder and rose among those with substance use disorders other than cannabis, the university reported.
How Many Addiction Treatment Facilities Offer Tobacco Cessation Medication
The most recent national count comes from the 2023 National Substance Use and Mental Health Services Survey, which researchers from the CDC and SAMHSA analyzed in an April 2025 Morbidity and Mortality Weekly Report. Of 14,620 substance use treatment facilities, 82.3 percent screened for tobacco use and 69.9 percent offered cessation counseling. Medication was scarcer. Nicotine replacement therapy was available at 40.2 percent of facilities, and bupropion or varenicline at 35.3 percent. A tobacco-free policy covering both smoking and vaping across all indoor and outdoor areas was reported by 33.9 percent.
Ownership tracked closely with policy. Among private for-profit substance use facilities, 20.1 percent were tobacco-free, compared with 42.2 percent of private nonprofits and 58.2 percent of public agencies. Residential programs, where patients live on site for weeks, reported a tobacco-free rate of 24.2 percent even though 61.0 percent of them offered nicotine replacement. Geography mattered more than either. New York reported tobacco-free policies at 76.0 percent of its substance use facilities and nicotine replacement at 75.8 percent; in Kentucky, 8.2 percent of facilities were tobacco-free.
The direction of travel is upward. In 2016, by the agencies’ earlier count, 47.4 percent of substance use facilities offered cessation counseling, against 69.9 percent seven years later. The authors caution that a 2021 survey redesign limits the comparison, and that the survey asks whether a service is offered, not how many patients receive it.
Smoking Cessation in Addiction Recovery: The Relapse Belief and the Evidence
Reluctance in the field has deep roots. The MMWR authors attribute the gap partly to the long normalization of smoking in behavioral health settings, partly to tobacco industry provision of reduced-cost or free cigarettes to treatment facilities, and partly to persistent misinformation that quitting smoking could undermine recovery from other substances.
The research has pointed the other way for two decades. In a 2004 meta-analysis of 19 randomized trials published in the Journal of Consulting and Clinical Psychology, Judith Prochaska, Kevin Delucchi, and Sharon Hall of the University of California, San Francisco found that smoking cessation interventions delivered during addiction treatment were associated with a 25 percent increased likelihood of long-term abstinence from alcohol and illicit drugs. They were candid about the limits. The interventions helped people quit smoking in the short run, but those effects were no longer significant at long-term follow-up. For program design, the more durable finding was that treating tobacco did not cost patients their sobriety.
Medication carried its own hesitation. For years varenicline and bupropion bore boxed warnings about serious psychiatric side effects, a label that weighed heavily in settings full of patients with co-occurring mental illness. In December 2016, after reviewing a large safety trial it had required of the manufacturers, the FDA removed that boxed warning from Chantix and the related language from Zyban’s, while keeping a description of the risks elsewhere on both labels.
Tobacco-Free Policy Requirements and Billing for Cessation Services
As of July 2024, 19 states had laws or regulations requiring tobacco-free policies at most substance use treatment facilities, and as of September 2024, nine required those facilities to make cessation treatment available, according to state policy tallies from the Public Health Law Center cited in the MMWR report. Federal tobacco control money has leaned the same way. Since 2020, CDC’s National Tobacco Control Program has required state health departments to address tobacco use among people with behavioral health conditions, and SAMHSA has funded a National Center of Excellence for Tobacco-Free Recovery since 2018. Indiana, the report notes, went from roughly 40 percent of state-funded behavioral health agencies routinely building tobacco dependence treatment into care plans in 2017 to more than 80 percent in 2023.
The billing scaffolding already exists. Cessation counseling is reported under CPT 99406 for sessions longer than three minutes and up to ten, and 99407 for sessions longer than ten. Medicare covers two cessation attempts a year with up to four counseling sessions each, according to its Part A and B contractor guidance; Medicaid and commercial coverage of counseling and medication varies by state and plan. Medicare’s valuation of both codes is set to rise in 2027. In its physician fee schedule final rule released November 4, CMS finalized its plan to fold smoking and tobacco use cessation services into the last year of a payment transition for timed behavioral health codes, which its July proposal described as applying the full 19.1 percent upward adjustment in a single step. For most outpatient addiction programs, a few minutes of documented counseling at intake will function as standard care rather than a meaningful revenue line.
Medication is where the operational burden concentrates. Dispensing nicotine replacement on a residential unit means stocking it, dosing it against how much a patient smoked, and coordinating with pharmacy benefits. Prescribing varenicline or bupropion requires a prescriber who sees the patient regularly, a role many smaller outpatient programs do not have on staff, though telepsychiatry has held up for medication management in ways that could fill some of that gap. The 2023 survey reflects that divide: hospital inpatient substance use programs offered nicotine replacement at 79.7 percent, outpatient programs at 35.6 percent.
Where Tobacco Treatment Fits in a Changing Addiction Treatment Market
The rest of addiction care is moving quickly. Overdose deaths have fallen by roughly a third, stimulants now drive a growing share of the deaths that remain, and long-acting injectable buprenorphine is turning a daily prescription into a billable clinical service. Each shift has prompted programs to revisit what they treat and how they are paid. Tobacco has rarely made that list, although the Mayo cohort suggests it outlasts the others as a cause of death among people who finish treatment.
New York’s tobacco-limited guidance lays out the trade-offs operators weigh. A residential program that bans cigarettes outright may see some patients leave against advice rather than go without, while one that allows scheduled smoking has to staff the breaks, store the packs, and log every lighter. OASAS has tried to balance the two by requiring counseling and medication whichever path a program takes, and by barring tobacco-limited programs from advertising the status on websites, brochures, or presentations.
SAMHSA’s later facility surveys will indicate whether the counseling gains of recent years have reached the medication shelf. The 2023 count remains the current benchmark. In it, roughly six in ten substance use facilities offered no nicotine replacement at all.
